William Ho, IN8bio CEO

IN8bio's 'off-the-shelf' gam­ma delta T cells stave off re­lapse for high-risk leukemia pa­tients in very ear­ly da­ta cut

With eyes set on the fu­ture of cell ther­a­py, re­searchers are look­ing to lever­age a grow­ing menagerie of im­mune cells to en­gi­neer a bet­ter gen­er­a­tion of tu­mor fight­ers. One type show­ing ear­ly promise is gam­ma delta T cells, and now an­oth­er biotech in that space is trot­ting out promis­ing — if lim­it­ed — re­sults.

Three acute myeloid leukemia pa­tients dosed with IN8bio’s off-the-shelf gam­ma delta T cells re­mained in re­mis­sion af­ter a stem cell trans­plant as long as 20 months af­ter re­ceiv­ing their cells, of­fer­ing an ear­ly vote of con­fi­dence for the small biotech’s ap­proach, the com­pa­ny said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.